Loading...
•
Mar 31, 2022
Bio-Techne Q3 2022 Earnings Report
Bio-Techne's third quarter results for fiscal year 2022 were released, showing revenue growth and strategic developments.
Key Takeaways
Bio-Techne reported a 19% increase in net sales, reaching $290.4 million, with organic growth of 17%. GAAP EPS was $1.48, and adjusted EPS was $2.14. The company highlighted strong performance in both Protein Sciences and Diagnostics and Genomics segments, and announced an exclusive agreement with Thermo Fisher Scientific.
Organic revenue increased by 17% to $290.4 million.
GAAP EPS was $1.48, and adjusted EPS reached a record $2.14.
Protein Sciences delivered organic growth of 16%, while Diagnostics and Genomics achieved 19% organic growth.
An exclusive agreement with Thermo Fisher Scientific to develop and commercialize the ExoTRU kidney transplant rejection test was announced.
Bio-Techne
Bio-Techne
Bio-Techne Revenue by Segment
Revenue by Segment
Protein Sciences Revenue
CapyFin.comDiagnostics & Spatial Bio Revenue
CapyFin.com Forward Guidance
No specific forward guidance was provided in the release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income